SANTA MONICA, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced that it has received an award from the Science and Technology Department of Zhejiang Province, one of the richest regions in China and known throughout the country for its focus on innovation. Aida was rewarded by the governmental authority because of its "clinical research and commercialization of Rh-Apo2L" as a "significant scientific and social developing project" recognized by the Science and Technology Department of Zhejiang Province. The Science and Technology Department of Zhejiang Province is the governmental administrative department for the entire science and technology industry in Zhejiang Province.
Mr. Jin Biao, Chairman of Aida Pharmaceuticals, stated, "We are very honored to have this major award bestowed on us by the Science and Technology Department of Zheijiang Province. The government has supported our efforts throughout Rh-Apo2L's development process." The award also includes a financial reward, totaling RMB1.2 million (US$164,982.47, as of January 2008).
About Aida Pharmaceuticals
Aida Pharmaceuticals is a product-focused pharmaceuticals company
engaged in the formulation, clinical testing, registration, manufacture,
sales and marketing of advanced pharmaceutical and genetic products in
mainland China. The Company's mission is to discover, develop and market
meaningful new therapies that improve human health. The Company has nine
product lines including its main product, Etimicin Sulfate, the first
antibiotic developed in China, which it manufactures and markets in powder,
liquid and transfusion form. Aida Pharmaceuticals, in operation since March
1999, is headquartered in Hangzhou, China with manufacturing, distribution
and sales points throughout mainland China. Aida is GMP certified in China
and ISO9002 certified for quality assurance and ISO14000 certified for
|SOURCE Aida Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved